EMEA-002051-PIP02-16

Human medicines European public assessment report (EPAR): Teizeild, teplizumab, Date of authorisation: 08/01/2026, Revision: 1, Status: Authorised

Revamp of marketing authorisation assessment templates

PSUSA/00002357/202508

Human medicines European public assessment report (EPAR): Mysildecard, sildenafil, Date of authorisation: 15/09/2016, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Entecavir Viatris (previously Entecavir Mylan), entecavir, Date of authorisation: 18/09/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Eltrombopag Viatris, eltrombopag, Date of authorisation: 12/12/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Duloxetine Viatris (previously Duloxetine Mylan), duloxetine, Date of authorisation: 19/06/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Darunavir Viatris (previously Darunavir Mylan), darunavir, Date of authorisation: 03/01/2017, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Ibandronic Acid Sandoz, ibandronic acid, Date of authorisation: 26/07/2011, Revision: 10, Status: Lapsed